Beyond the target: implications of Wnt pathway inhibitors on bone health.

foscenvivint (PRI724) - PRISM Pharma, Ohara Pharma

vantictumab (OMP-18R5) - Mereo Biopharma

ipafricept (OMP-54F28) - Mereo Biopharma

niclosamide - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42399539

Arnaud Vanjak; Clément Nachef; Eric Haÿ; Martine Cohen-Solal; Thomas Funck-Brentano

Jul 4, 2026